CASE STUDY

LifeSci Index Partners

Challenge


LifeSci Index Partners, an expert in the biotech investing space, partnered with Arro to introduce their new funds to the public in December 2014. As niche, focused biotechnology funds, LifeSci faced an uphill battle to bridge the educational gap and make a case for their ETFs.



Solution


Arro developed a complete, end-to-end PR campaign to introduce the two funds, BBC (the Biotechnology Clinical Trials Fund) and BBP (the Biotechnology Products Fund) to the public. By leveraging the firm’s expertise and insight in the biotechnology space, we were able to craft a compelling narrative around these two funds, focused in part on what other biotech funds were neglecting to include or overweighting.



Results


The concerted effort paid off, resulting in significant media coverage from the Financial Times, Financial Advisor Magazine, and CNBC. As of 6/25/20, the funds boasted a combined AUM of $76 million.